Tumor heterogeneity confounds cancer diagnosis and the outcome of therapy, necessitating analysis of tumor cell subsets within the tumor mass. Elevated expression of hyaluronan (HA) and HA receptors, receptor for HA-mediated motility (RHAMM)/HA-mediated motility receptor and cluster designation 44 (CD44), in breast tumors correlates with poor outcome. We hypothesized that a probe for detecting HA-HA receptor interactions may reveal breast cancer (BCa) cell heterogeneity relevant to tumor progression. A fluorescent HA (F-HA) probe containing a mixture of polymer sizes typical of tumor microenvironments (10-480 kDa), multiplexed profiling, and flow cytometry were used to monitor HA binding to BCa cell lines of different molecular subtypes. Formulae were developed to quantify binding heterogeneity and to measure invasion in vivo. Two subsets exhibiting differential binding (HA −/low vs. HA high ) were isolated and characterized for morphology, growth, and invasion in culture and as xenografts in vivo. F-HA-binding amounts and degree of heterogeneity varied with BCa subtype, were highest in the malignant basal-like cell lines, and decreased upon reversion to a nonmalignant phenotype. Binding amounts correlated with CD44 and RHAMM displayed but binding heterogeneity appeared to arise from a differential ability of HA receptor-positive subpopulations to interact with F-HA. HA high subpopulations exhibited significantly higher local invasion and lung micrometastases but, unexpectedly, lower proliferation than either unsorted parental cells or the HA −/low subpopulation. Querying F-HA binding to aggressive tumor cells reveals a previously undetected form of heterogeneity that predicts invasive/metastatic behavior and that may aid both early identification of cancer patients susceptible to metastasis, and detection/therapy of invasive BCa subpopulations.
Tumor heterogeneity confounds cancer diagnosis and the outcome of therapy, necessitating analysis of tumor cell subsets within the tumor mass. Elevated expression of hyaluronan (HA) and HA receptors, receptor for HA-mediated motility (RHAMM)/HA-mediated motility receptor and cluster designation 44 (CD44), in breast tumors correlates with poor outcome. We hypothesized that a probe for detecting HA-HA receptor interactions may reveal breast cancer (BCa) cell heterogeneity relevant to tumor progression. A fluorescent HA (F-HA) probe containing a mixture of polymer sizes typical of tumor microenvironments (10-480 kDa), multiplexed profiling, and flow cytometry were used to monitor HA binding to BCa cell lines of different molecular subtypes. Formulae were developed to quantify binding heterogeneity and to measure invasion in vivo. Two subsets exhibiting differential binding (HA −/low vs. HA high ) were isolated and characterized for morphology, growth, and invasion in culture and as xenografts in vivo. F-HA-binding amounts and degree of heterogeneity varied with BCa subtype, were highest in the malignant basal-like cell lines, and decreased upon reversion to a nonmalignant phenotype. Binding amounts correlated with CD44 and RHAMM displayed but binding heterogeneity appeared to arise from a differential ability of HA receptor-positive subpopulations to interact with F-HA. HA high subpopulations exhibited significantly higher local invasion and lung micrometastases but, unexpectedly, lower proliferation than either unsorted parental cells or the HA −/low subpopulation. Querying F-HA binding to aggressive tumor cells reveals a previously undetected form of heterogeneity that predicts invasive/metastatic behavior and that may aid both early identification of cancer patients susceptible to metastasis, and detection/therapy of invasive BCa subpopulations.
tumor cell heterogeneity | hyaluronan binding | heterogeneity index B reast tumors display substantial heterogeneity driven by genetic and epigenetic mechanisms (1) (2) (3) . These processes select and support tumor cell subpopulations with distinct phenotypes in proliferation, metastatic/invasive proclivity, and treatment susceptibility that contribute to clinical outcomes. Currently, there is a paucity of biomarkers to identify these subpopulations (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Although detection of genetic heterogeneity may itself be a breast cancer (BCa) prognostic marker (3, (13) (14) (15) , the phenotypes manifested from this diversity are context-dependent. Therefore, phenotypic markers provide additional powerful tools for biological information required to design diagnostics and therapeutics. Glycomic approaches have enormous potential for revealing tumor cell phenotypic heterogeneity because glycans are themselves highly heterogeneous and their complexity reflects the nutritional, microenvironmental, and genetic dynamics of the tumors (16) (17) (18) .
We used hyaluronan (HA) as a model carbohydrate ligand for probing heterogeneity in glycosaminoglycan-BCa cell receptor interactions. We reasoned this approach would reveal previously undetected cellular and functional heterogeneity linked to malignant progression because the diversity of cell glycosylation patterns, which can occur as covalent and noncovalent modifications of proteins and lipids as well as different sizes of such polysaccharides as HA, is unrivaled (16, 17, 19) . In particular, tumor and wound microenvironments contain different sizes of HA polymers that bind differentially to cell receptors to activate signaling pathways regulating cell migration, invasion, survival, and proliferation (19) (20) (21) (22) .
More than other related glycosaminoglycans, HA accumulation within BCa tumor cells and peritumor stroma is a predictor of poor outcome (23) and of the conversion of the preinvasive form of BCa, ductal carcinoma in situ, to an early invasive form of BCa (24) . HA is a nonantigenic and large, relatively simple, unbranched polymer, but the manner in which it is metabolized is highly complex (19, 25) . There are literally thousands of different HA sizes in remodeling microenvironments, including tumors. HA polymers bind to cells via at least six known receptors (16, 19, 20, (26) (27) (28) (29) (30) (31) (32) . Two of these, cluster designation 44 (CD44) and receptor for HA-mediated motility/HA-mediated motility receptor (RHAMM/HMMR), form multivalent complexes with different ranges of HA sizes (19, 29, 33) , and both receptors are implicated in BCa progression (19-21, 23, 29, 30, 33-36) .
Significance
Tumor heterogeneity is a poorly understood phenomenon. We lack biomarkers for identifying aggressive primary tumor subsets that give rise to metastases and impact early cancer detection and treatment. Many solid tumors are known to accumulate hyaluronan (HA), a glycosaminoglycan, which is also produced by the tumor cells themselves. We report a quantitative approach for uncovering breast cancer heterogeneity using fluorescent HA to detect differential binding patterns to CD44 and RHAMM/HMMR receptors. This approach permits identification of tumor-cell subsets that bind high levels of HA, and may be applicable to other ligands/receptors and disease models. Despite representing the invasive/metastatic subset of parental tumors, unexpectedly, the high HA-binding subset was slow-growing, and is thus likely to be a source of dormancy and relapse.
Elevated CD44 expression in the peritumor stroma is associated with increased relapse (37) , and in primary BCa cell subsets may contribute to tumor initiation and progression (38) (39) (40) . Elevated RHAMM expression in BCa tumor subsets is a prognostic indicator of poor outcome and increased metastasis (22, 33, 41) . RHAMM polymorphisms may also be a factor in BCa susceptibility (42, 43) .
We postulated that multivalent interactions resulting from mixture of a polydisperse population of fluorescent HA (F-HA) sizes, typical of those found in remodeling microenvironments of wounds and tumors (19, 20, 29) , with cellular HA receptors would uncover a heterogeneous binding pattern useful for sorting tumor cells into distinct subsets. We interrogated the binding of F-HA to BCa lines of different molecular subtypes, and related binding/uptake patterns to CD44 and RHAMM display, and to tumor cell growth, invasion, and metastasis. − , and is currently one of the most difficult BCa to treat because it is commonly chemoresistant and exhibits early metastases with consequent poor 5-y survival rates (48) (49) (50) (51) (52) . Few of these BCa subtypes have been characterized for CD44 or RHAMM expression (31, 53, 54) , and none to our knowledge have been examined for HA binding. Because HA receptor display is a prerequisite for HA binding, we used mRNA microarray repositories in Oncomine (http://oncomine.com) to assess expression of known HA receptors (19) in primary BCa. Coexpression of CD44 and RHAMM mRNA occurred in all subtypes but was highest in triple-negative tumors (SI Results and Tables S1 and S2). In general agreement with Oncomine databanks, CD44 and RHAMM proteins were displayed in human BCa lines of different molecular subtypes (Table S3) .
HA Binding Is Heterogeneous. To determine whether HA binding revealed BCa cellular heterogeneity related to HA receptor display, we synthesized a F-HA probe containing a polydisperse mixture of polymer sizes typical of tumor microenvironments (Fig. 1A) , and quantified F-HA binding using flow cytometry (Fig. 1B and Table 1 ). Each cell line bound F-HA, but the total amount that bound varied (as calculated by fluorescence geometric mean value of positive binding of peak 2) and correlated with the levels of CD44 and RHAMM protein display. Thus, MDA-MB-231 and T4-2 cells, which express high levels of CD44 and RHAMM, showed higher F-HA binding than MCF-7 or SKBR-3 cells, which display lower levels of CD44 and RHAMM (Table 1) .
Unexpectedly, F-HA binding was heterogeneous in all cell lines (+F-HA in Fig. 1B ). Thus, profiles followed a non-Gaussian pattern composed of either two major peaks (e.g., MDA-MB-231) or one peak and a positively skewed tail (e.g., SKBR-3). A Shapiro-Wilk normality test confirmed that F-HA-binding profiles significantly deviated from normality as measured by the value W (55) (MDA-MB-231: 0.8528; T4-2: 0.7245; MCF-7: 0.6505; and SKBR-3: 0.6265; P < 0.001). However, this measure did not allow us to compare the degree of heterogeneity among the F-HA-binding profiles. Therefore, we developed a heterogeneity index (Het.I), which measures the median of the total F-HA binding and is weighted by the differential binding:
where AUC 2 /AUC 1 is a ratio of areas under the curves of positive binding (AUC 2 in Fig. 1B; area 2 shown by the red arrow) and the first binding peak (AUC 1 in Fig. 1B; area 1 shown by the black arrow). Het.I was highest for MDA-MB-231 (33.6) followed by T4, SKBR-3, and MCF-7 (4.3, 3.5, and 1.4, respectively). The rank orders for both binding heterogeneity and binding levels were independent of the type of fluorescent label used and exposure time to F-HA from 2 to 120 min (Fig. 1C) .
To determine if differences in F-HA binding persisted under physiologically relevant conditions, we grew cells in 3D lamininrich gels, which mimic aspects of tumor microenvironments (56) . The rank order of F-HA-binding levels did not change (e.g., MDA-MB-231 vs. SKBR-3 in Fig. 1D) , although the overall level of binding and Het.I increased due to amplification of peak 2 in 3D culture (compare MDA-MB-231 in Fig. 1 B and E). Thus, these properties were stable regardless of culture conditions (2D vs. 3D).
The most malignant cell line, the triple-negative MDA-MB-231 (48, 49) , exhibited the highest F-HA binding and Het.I. To determine whether these two parameters were functionally linked to malignancy, we took advantage of our ability to revert MDA-MB-231 cells to a more nonmalignant phenotype by ablating β1 integrin and PI3K signaling in 3D culture (57) . The F-HA-binding profile of reverted MDA-MB-231 cells remained heterogeneous; however, both the degree of binding heterogeneity (indicated by Het.I) and total F-HA binding were reduced by 4.8-and 1.4-fold, respectively (Fig. 1E ). These results indicate that HA-binding level and binding heterogeneity are linked to a malignant phenotype.
HA-Binding Heterogeneity Arises from Distinct Abilities of HA ReceptorPositive Subpopulations to Interact with HA. To examine whether differences in tumor cell HA receptor display accounted for quantitative differences in F-HA-binding heterogeneity (Fig. 1B) , we measured cell-surface CD44 and RHAMM before F-HA exposure using flow cytometry (Fig. S1 ). Flow cytometry profiles lacked the second peak and positively skewed tails observed for F-HA binding, showing that neither CD44 nor RHAMM display mirrored F-HA-binding heterogeneity. Therefore, the highly heterogeneous flow cytometry profiles of F-HA binding did not appear to arise from a similarly heterogeneous display of HA receptors by tumor cell subpopulations.
Previous studies have shown that HA receptors generally do not bind constitutively to HA (58, 59) . We therefore postulated that HA-binding heterogeneity arose from differences in receptor activation or binding affinity, which would be detected as a differential binding of the CD44
+ and/or RHAMM + subpopulations to F-HA. We developed a sensitive multiplexed detection assay to simultaneously monitor CD44 and RHAMM display as well as F-HA binding to live BCa cells (Fig. 2) . We used MDA-MB-231 cells because these coexpress CD44 and RHAMM, exhibit the highest F-HA binding and heterogeneity, and are widely used as a malignant triple-negative BCa model (48) (49) (50) (51) (52) .
As expected, controls (untreated or incubated with nonimmune IgG) exhibited background staining (e.g., grouping into CD44 − /RHAMM − quadrants) ( Fig. 2A , i) whereas incubation with CD44 and RHAMM antibodies resulted in staining above these control levels ( Fig. 2 A, ii and iii) consistent with previous studies (31, 54) . All cells displayed high CD44 levels ( Fig. 2A , ii) whereas the majority of the cells exhibited low but detectable RHAMM display ( Fig. 2A, iii) . F-HA binding was heterogeneous and spanned from −/− to −/+ quadrants as expected from Fig. 1  (Fig. 2B, i) . Multiplexed analyses showed that some CD44
+ cells did not bind to F-HA (+/− quadrant in Fig. 2B , ii). However, all F-HA + cells displayed CD44 (HA + /CD44 + in Fig. 2B , ii) and all RHAMM + tumor cells bound F-HA (HA + /RHAMM + in Fig.  2B , iii). Consistent with these multiplexed assays, a RHAMM mimetic peptide significantly reduced F-HA probe uptake (Fig.  2C, i) , and antibodies to CD44 almost completely blocked binding and uptake of the F-HA probe into MDA-MB-231 cells (Fig. 2C, ii) . These results confirmed the importance of CD44 and RHAMM in F-HA binding to MDA-MB-231 tumor cells and suggested that differential binding of F-HA to RHAMM and CD44 might generate some of the observed probe binding heterogeneity.
We next analyzed the internalization and subcellular trafficking of the F-HA probe to determine whether these might also play a role in binding heterogeneity. Fluorescence microscopy confirmed F-HA uptake was heterogeneous in 3D and in 2D cultures (Fig. 2D) ; F-HA accumulated at the cell membrane, particularly in cell processes resembling invadopodia (Fig. 2D, ii) , and was internalized into multiple subcellular compartments including the cytoplasm and nucleus ( Fig. 2C, i ; no peptide control and 2D). Transmission electron microscopy (TEM) analysis confirmed the presence of Au-HA nanoparticles in the nucleus (Fig. 2E) . Simultaneous exposure of cells to F-HA and the RHAMM mimetic peptide (29) , which blocks HA-RHAMM interactions, prevented nuclear accumulation of F-HA and reduced its cytoplasmic and perinuclear accumulation (Fig. 2C, i) . Although CD44 is the acknowledged endocytic receptor that internalizes HA in most cell types (60), these results suggested that RHAMM had a function in moving internalized F-HA into the nucleus. To validate F-HA internalization by flow cytometry, we compared F-HA binding at 4°C vs. 37°C. Binding heterogeneity was reduced at 4°C Scores are determined by FACS geometric mean and median values of cell-surface-bound F-HA or CD44 and RHAMM displays. Degree of positivity is measured by comparing the geometric mean of sample data with that of control (intact cells before addition of F-HA or isotype-matched nonimmune IgG treated) sample data.
( Fig. 2F) confirming F-HA binding/uptake is temperaturedependent, consistent with a role for receptor internalization and trafficking in this phenotype.
To determine whether dynamic changes in tumor subpopulations that affect their ability to bind F-HA also contribute to heterogeneity, we assessed whether F-HA-binding properties are stable or dynamic within the two subpopulations. Subpopulations that bound no or low amounts of F-HA (HA −/low in Fig. S2A , i) were therefore isolated and then reexposed to F-HA after growth in 2D culture for 7 d, which is a time when the F-HA probe had been depleted (Fig. S2A, ii) . Readdition of F-HA to these cells (HA −/low +F-HA in Fig. S2B ) resulted in HA −/low cells retaining the first binding peak but demonstrated a failure of these cells to generate the second peak to the extent of the parent cell population, as quantified by their nearly twofold reduced Het.I. These results suggest that the HA −/low bind F-HA stochastically, but the subpopulation of parental tumor cells that binds high levels of F-HA appears to be stable. These results also suggest that F-HA-binding heterogeneity is not due to dynamic changes per se in parental tumor cell subpopulations.
Collectively, these findings suggest that (i) use of F-HA uncovers a stable form of BCa heterogeneity not previously detected with anti-CD44 or -RHAMM antibodies, and (ii) F-HA binding likely results from a combinatorial model of stochastic and stable binding as well as differential receptor display/binding affinity and trafficking to generate heterogeneity. and HA high subpopulations using FACS (Becton Dickinson) (Fig. 3A) . Sorted cells were expanded in 2D then examined for their proliferative and invasive potential. Despite the disappearance of F-HA by 7 d in tumor cells (Fig. S2A, ii) , the HA −/low and HA high subpopulations exhibited distinct and stable phenotypes (Fig. 3 B-E) . HA −/low cells uniformly adhered to the substratum and proliferated rapidly (Fig. 3B, i, Left) reaching confluence by day 7 (Fig. 3B, i, Right) . HA high subpopulations attached more slowly (Fig. 3B , ii, Left) and failed to reach confluence by day 7 (Fig. 3B, ii, Right) . In 2D colony-forming assays, HA −/low cells achieved a higher number and a 23% larger size of colonies than HA high cells (Fig. 3B, Center) . cells ( Fig. 3 C and D) . The morphology of HA high colonies in the 3D cultures suggested that they might be more invasive than HA −/low colonies ( Fig. 3 C and D) . Matrigel invasion assays confirmed the above (Fig. 3E) .
Real-Time Analysis of HA Uptake and Extravasation in Chick Chorioallantoic Membranes. To determine if F-HA binding/uptake occurs in an in vivo-like microenvironment and is associated with invasion, we used the chick chorioallantoic membrane (CAM) model, which allows for real-time monitoring of early uptake events and tumor cell interactions within microvessels (61) (62) (63) (64) . The endothelial lumen was marked (green) before injection of fluorescent MDA-MB-231 cells (red) mixed with F-HA (blue) into a CAM vein (Fig. 4 A-E) . Ten to 15 min after injection, F-HA was present within the blood vessels but had not yet been taken up into the interstitial spaces (Fig. 4A) . Two hours after injection, F-HA binding/uptake occurred in the CAM vessels and F-HA vesicles were present inside tumor cells that had flattened onto the vessel endothelium, but had not yet extravasated into interstitial spaces (Fig. 4 A and B) . All adherent tumor cells had taken up F-HA. To assess whether increased HA uptake identified invasive cells, the interaction of MDA-MB-231 cells with CAM microvessels was monitored before and after exposure to F-HA (Fig. 4 C-E) . A subset of parental untreated MDA-MB-231 cells labeled with cell tracker (pseudocolored red) extravasated and formed viable interstitial tumor colonies surrounding and at a distance from vessels (pseudocolored green) by 72 h (Fig.  4C) . MDA-MB-231 cells injected together with F-HA showed more efficient extravasation than untreated tumor cells by 24 h (Fig. 4E) . Thus, tumor cells bind to and take up HA in this model, and are more efficient at attaching to and extravasating through endothelium than untreated cells. Fig. 5A, i) grew at a rate comparable to the HA −/low tumor subpopulation (black in Fig. 5A,  i) , whereas the HA high subpopulation (red in Fig. 5A , i) grew more slowly. Wet weight measurements at week 8 mirrored this difference in tumor growth (Fig. 5A, ii) .
H&E-stained tissue sections showed that all tumor xenografts formed high-grade adenocarcinomas. We observed six histological phenotypes of parental xenografts (Fig. 5B) , and analyzed the distribution of histological "signatures" on a per tumor per mouse basis (Fig. 5C, i) . Both HA −/low and HA high tumors exhibited part of the parental histology signatures and these occurred at different frequencies. Spindle foci, perivascular invasion, muscle invasion, and lymphovascular invasion occurred at a higher frequency in HA high than either HA −/low or parental tumors (Fig. 5C,  i) , likely because sorting based on F-HA probe binding allowed enrichment of a highly invasive subpopulation present in small amounts in the parental line. HA −/low tumors exhibited fewer spindle cell foci and less perivascular invasion than parental or HA high tumors, and showed no evidence of lymphatic or muscle invasion. To quantify these differences by a single value, we defined a local invasion index (LII) comprising the sum of perivascular, muscle, and lymphovascular invasion frequencies. The LII was 63% for parental tumors, 12% for HA −/low , and 99% for HA high tumors (Fig. 5C, ii) , revealing an overall 8.2-fold higher invasive capacity in HA high compared with HA −/low subpopulations. The LII for unsorted parental tumors was not changed by their exposure to F-HA before injection into mice (66% vs. 63%, respectively). Lung and liver tissues were examined for evidence of metastases. Proliferating human tumor cells were identified by human-specific anti-Ki67 antibodies. No metastases were detected in liver, but micrometastases were observed in lung (Fig.  5D ). Quantification of these showed a significantly greater number of micrometastases in lungs of animals injected with HA high vs. HA −/low subpopulations. These results show that absent or low HA binding is associated with enhanced primary tumor proliferation but low invasion and lung metastasis, whereas high HA binding is linked to enhanced invasion and metastasis but slow proliferation of primary tumor cells.
Discussion
It has long been recognized that tumors are heterogeneous and comprise multiple subpopulations that likely provide a survival and growth advantage for primary tumors and their metastases (65) (66) (67) (68) . Tumor cell heterogeneity confounds our understanding of tumor progression, relapse, and therapy (3, 7, 69) . Despite advances in genotypic and phenotypic heterogeneity assessment strategies, biomarkers, in particular those identifying the presence of aggressive and/or resistant subpopulations, are urgently needed for the design of effective BCa diagnostics and therapies.
Because some phenotypic diversity can be simulated in many BCa cell lines (7, 70) , we tested the possibility that patterns of exogenous ligand binding to receptors in aggressive cancer cells might offer a new method for profiling cellular and functional heterogeneity. We chose HA because the production and metabolism of this glycosaminoglycan is linked to cancer progression and poor clinical outcome (20, 21, 71, 72) . We profiled multivalent interactions of F-HA and HA receptors in live cells. We discovered that subtype-specific quantitative differences among binding levels of F-HA to BCa cancer cell lines correlated with HA receptor display, but all F-HA-binding profiles were heterogeneous. To obtain a quantitative measure of binding heterogeneity, we developed Het.I. The values measured by Het.I suggested that HA binding follows a combinatorial model by which some cells bind HA stochastically, whereas other subpopulations exhibit a stable ability to bind HA (Fig. S2) .
Among the different cell lines we used, the most metastatic and triple-negative basal-like MDA-MB-231 exhibited both the highest HA-binding level and HA-binding heterogeneity, suggesting that these properties correlate with the malignant state. To directly confirm this correlation without altering the oncogenic mutations of this cell line, we reverted the malignant phenotype to a more nontumorigenic and less malignant phenotype in 3D culture (57) . The less malignant phenotype corresponded with a lower HA-binding level and reduced binding heterogeneity. These results suggest that F-HA probe binding to cells provides a measure for determining the degree of malignant behavior and underscores the importance of architecture and organization as crucial parameters in malignancy (73) .
Because CD44/RHAMM displays did not mirror HA-binding heterogeneity ( Fig. S1 and Fig. 2) , we monitored multiplexed interactions of the F-HA probe with CD44 and RHAMM, and showed that CD44 and RHAMM interactions with F-HA occurred heterogeneously. Not all CD44 receptors that were present on the cells interacted with F-HA. In addition, surface-bound F-HA changed in a temperature-dependent manner and F-HA was observed in the cytoplasm and nucleus of cells at 37°C, indicating internalization of HA as a contributing factor to uptake heterogeneity. Because the F-HA conjugate is a mixture of different sizes of HA molecules (molecular weight range: 10-480 kDa; molecular weight average: 240 kDa), it is likely that both receptor trafficking and size-related differential binding contribute to the observed heterogeneity.
Using xenografts and 3D cultures, we found a surprising link between binding heterogeneity and stable differences in the phenotypes and tumorigenicity of these subpopulations. These were either poorly invasive/metastatic and fast-growing (HA −/low ) or highly invasive/metastatic but slow-growing (HA high ). This finding is at odds with the conventional paradigm that rapidly proliferating tumors are also invasive and likely to metastasize. Our screening method has thus uncovered a type of tumor heterogeneity that may be associated with epigenetic mechanisms used by breast tumor cells for acquiring aggressive behavior and may be useful for identifying new therapeutic targets. Our results also suggest that the presence of HA high subpopulations in primary tumors may indicate a susceptibility for metastasis and predict tumor recurrence and therapy resistance. The probe may have revealed previously existing heterogeneity due to other as yet unknown factors, and/or it may be acting as a functional probe that signals and forces cells into a stable differentiation program to restrict proliferation but increase motility/invasion. HA has the potential to accomplish the latter effect because it is well-documented to activate signaling cascades that control such cellular functions (19-21, 71, 72) ; however, some of these effects have been reported as transient. Because the F-HA signal disappeared by 7 d and the LII for unsorted parental tumors was not changed by their exposure to F-HA before injection into mice, we currently favor the former possibility.
In summary, use of F-HA uncovers a stable form of BCa heterogeneity that has not been detected previously with anti-CD44 or -RHAMM antibodies. The demonstration that BCa lines, which are generally considered homogeneous phenotypically, are in fact quite heterogeneous with respect to HA binding, raises the possibility that other clinically relevant traits may stably segregate specific subpopulations in tumor cell lines, which could ultimately be applied to probing primary tumor heterogeneity. Because HA is a biocompatible natural polymer and is welltolerated in vivo (20, 21, 74, 75) , HA-based probes can be readily used as part of clinical heterogeneity profiling. The quantitative approaches and the Het.I formula for measuring HA-binding differences may facilitate incorporation of heterogeneity as a determining factor in diagnosis and therapy of metastatic cancers, and could be used to detect heterogeneity of other measurable phenotypic traits or those introduced by biophysical cues (74, 75) in 3D micro-/nanoenvironments. This type of subpopulation analysis points to the importance of taking tumor cell heterogeneity, even within tumor cell lines, into consideration, and may also provide more clinically relevant models for assessing treatment efficacy.
Materials and Methods
Two-Dimensional Cell Culture. HMT-3522 S1, HMT-3522 T4-2 mammary epithelial cells (76) (77) (78) , MCF-10A, Hs578T, MCF-7, MDA-MB-231, and SKBR-3 (American Type Culture Collection) were cultured (79) (SI Materials and Methods).
Three-Dimensional Cell Culture. Cells were prepared for culturing on top of Matrigel (BD Biosciences), a laminin-rich gel (lrECM) (56) (SI Materials and Methods). Reversion of 3D MDA-MB-231 cells was performed using AIIB2 and LY294002 reagents (57) and cells were extracted from 3D lrECM (56) (SI Materials and Methods).
F-HA Probe Synthesis. Medical-grade HA (Hyal Pharmaceutical), which contained a mixture of HA polymer sizes with a range from 10 kDa up to 480 kDa (molecular weight average: 240 kDa), was conjugated to Alexa Fluor or Texas Red (TR) (Invitrogen) through hydrazide coupling (SI Materials and Methods). The conjugation procedure did not detectably affect the HA polymer size range.
F-HA Probe Binding/Uptake. Subconfluent cells were grown to maximize RHAMM surface display (31, 54) , and were exposed to either Alexa Fluor 647 (A 647 )-HA (1 × 10 6 cells per mL PBS with 1 mL of A 647 -HA at 433 μg HA/mL) in suspension at 4°C in the dark or to A 647 -HA and TR-HA at 37°C in the dark in 2D and 3D cultures (SI Materials and Methods). Immunofluorescence Detection of Human Ki67. Tissues were deparaffinized in two 5-min cycles of 100% xylene then rehydrated in four 2-min cycles of 100% (vol/vol) EtOH, 95% EtOH, 70% EtOH, and 50% EtOH, followed by a rinse in PBS for 2 min before staining with anti-Ki67 antibody for detection of metastases (SI Materials and Methods).
Statistical Analysis. Oncomine data banks were investigated as described (SI Materials and Methods and SI Results). Deviation from normal distribution was analyzed by the Shapiro-Wilk normality test (55) using Prism 5.0 software (GraphPad Inc.) after log transformation. A W value of 1 indicated a normal distribution with P < 0.001 considered significant. Experimental groups were compared using Student t tests with P < 0.05 considered significant.
